RetinalGenix Technologies (RTGN) Research & Development (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Research & Development of $117064.0 for Q1 2026, up 785.91% on a YoY basis from $13214.0 in Q1 2025, and up 235.02% sequentially from $34942.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Research & Development (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Research & Development data on file, last reported at $117064.0 in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 785.91% year-over-year to $117064.0; the trailing twelve-month figure through Mar 2026 stood at $186890.0 (down 38.4% YoY), and the FY2025 full-year result was $83040.0, down 77.75% from the prior year.
- Research & Development improved to $117064.0 in Q1 2026, from $34942.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $317819.0 in Q4 2022 to a low of $13214.0 in Q1 2025.
- A 5-year average of $112165.5 and a median of $102977.0 in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development tumbled 84.1% in 2025 and surged 785.91% in 2026, its largest moves.
- Tracing RTGN's Research & Development over 5 years: stood at $317819.0 in 2022, then sank by 83.04% to $53896.0 in 2023, then soared by 93.47% to $104271.0 in 2024, then tumbled by 66.49% to $34942.0 in 2025, then surged by 235.02% to $117064.0 in 2026.
- Business Quant data shows RTGN's Research & Development at $117064.0 in Q1 2026, $34942.0 in Q4 2025, and $20454.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 767.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 413.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 671.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 516.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 263.30 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -461.27 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 345.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 117,064.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 117,064.00 |
| Dec 31, 2025 | 34,942.00 |
| Sep 30, 2025 | 20,454.00 |
| Jun 30, 2025 | 14,430.00 |
| Mar 31, 2025 | 13,214.00 |
| Dec 31, 2024 | 104,271.00 |
| Sep 30, 2024 | 102,977.00 |
| Jun 30, 2024 | 82,926.00 |
| Mar 31, 2024 | 83,097.00 |
| Dec 31, 2023 | 53,896.00 |
| Sep 30, 2023 | 89,778.00 |
| Jun 30, 2023 | 152,577.00 |
| Mar 31, 2023 | 227,932.00 |
| Dec 31, 2022 | 317,819.00 |
| Sep 30, 2022 | 198,504.00 |
| Jun 30, 2022 | 135,439.00 |
| Mar 31, 2022 | 157,493.00 |
| Dec 31, 2021 | 182,244.00 |
| Sep 30, 2021 | 200,899.00 |
| Jun 30, 2021 | 159,941.00 |